In my latest Guardian
column, "News Corp Kremlinology: what do the Times paywall numbers mean?" I have a good rummage around the mysterious figures released by The Times
earlier this month on the performance of its vaunted pay-for-news scheme. The Times
released the numbers with a lot of triumphant accompaniment, but I'm not clear on whether their figures can be taken of indication of anything, except, perhaps, a reluctance to report in full on their experiment's performance.
Here's what the Times will say: about 50,000 of the current paid users are on a monthly subscription of some sort: £8.66, £1, or free with a TalkTalk subscription. They will not disclose how many £1 trial users turn into £8.66 users, or how many sustain their £8.66 subscription into the second or third month. However, the anonymous official spokesperson did say that whichever users are remaining after three months are more than 90% likely to stump up for a fourth month. From this, I think we can safely assume that lots less than 90% of paid users stick around for a second month, and of those, less than 90% sustain themselves for a fourth month.
News Corp Kremlinology: what do the Times paywall numbers mean?
But the Times isn't saying.
The remaining 50,000, of course, are people who paid £1 for a single day's access. Some number of these converted to monthly subscribers.
Some number bought a second article. How many? The Times isn't saying.
So, best case: there are 50,000 paid subscribers, all of whom got there by paying £1 for an article, converted immediately to £1 monthly subscriptions and now pay £8.66 every month (or £9.99 in the case of iPad users who want to pay extra for the privilege of not being allowed to access the website).
Worst case: 50,000 people tried a day pass and left. 20,000 TalkTalk subscribers got a free subscription with their phone which they may or may not know or care about. 5,000 people use it with an iPad.
75,000 people tried a £1 month trial. 40,000 of them signed up for a second month, 30,000 of them for a third, and 25,000 stayed on for a fourth month.
Gabriella Corley is a 9 year old with Type I diabetes who’s allergic to the insulin covered by her low-income parents’ healthcare; to live, she must take Sanofi’s proprietary Apidra brand insulin, which has increased in price by 1,123% since 1996, and which is only covered to 25% by her insurer’s Pharmacy Benefit Manager, CVS.
Since the earliest days of ecommerce, analysts have predicted that retailers would use their estimations of their customers’ willingness to pay to invisibly, instantaneously reprice their goods, offering different prices to each customer.
The Intercept publishes a previously-unseen set of Snowden docs detailing more than $500,000,000 worth of secret payments by the Japanese government to the NSA, in exchange for access to the NSA’s specialized surveillance capabilities, in likely contravention of Japanese privacy law (the secrecy of the program means that the legality was never debated, so no […]
Bamboo has lots of uses beyond just being panda food. Things like bikes, roads, scaffolding, and musical instruments are made from the fast-growing grass. But unless you are participating in a tropical-themed LARP, you probably wouldn’t want a shirt made from bamboo stalks. So why do bamboo bed sheets make any sense? Because yarn extracted from […]
If you want to work in tech, but don’t have any desire to code web apps to help businesses sell things to other business, you might want to consider a career in cybersecurity. Judging from the apparent complete infiltration of Russian hackers in American cyberspace, it seems fair to speculate that there’s a major shortage of […]
All moms are different. But all moms like getting flowers on Mother’s Day, and that’s a fact (not, however a fact we can document in any fashion.) Instead of getting chewed out for forgetting to call her on the second Sunday of May, you can take care of it ahead of time with Teleflora’s flower […]